Research Article
Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer
Table 4
Univariate and multivariate analyses of distance disease-free survival.
| | Characteristic | Univariate analysis | Multivariate analysis | | HR (95% CI) | value | HR (95% CI) | value |
| | Age | ≤60/>60 | 1.214 (0.985–1.125) | 0.421 | | | | Sex | Female/male | 0.621 (0.34–1.263) | 0.127 | | | | Tumor site | Head/body/tail | 0.772 (0.438–1.248) | 0.337 | | | | Tumor size (cm) | | 1.187 (0.674–2.062 | 0.543 | | | | Tumor volume (cm3) | ≤37/>37 | 2.364 (1.059–4.685) | 0.007 | 2.856 (1.196–7.398) | 0.024 | | Local recurrence | ≤6 mo/>6 mo | 3.432 (1.406–8.125) | 0.006 | 0.523 (0.135–1.420) | 0.231 | | WBC (×109) | ≤10/>10 | 1.128 (0.364–2.825) | 0.858 | | | | HGB (g/L) | ≤120/>120 | 0.644 (0.345–1.670) | 0.403 | | | | PLT (×109) | ≤300/>300 | 1.218 (0.578–2.567) | 0.628 | | | | ALT (U/L) | ≤40/>40 | 0.767 (0.358–1.716) | 0.504 | | | | AST (U/L) | ≤40/>40 | 0.484 (0.205–1.561) | 0.176 | | | | ALP (U/L) | ≤100/>100 | 0.921 (0.546–1.950) | 0.703 | | | | CA19-9 level | ≤35/>35 | 1.638 (0.720–3.882) | 0.225 | | | | Complications | Yes/no | 1.382 (0.678–2.821) | 0.363 | | | | IRE | With/without GEM | 0.326 (0.192–0.752) | 0.014 | 0.385 (0.202–0.654) | 0.021 |
|
|
IRE: irreversible electroporation; GEM: gemcitabine; HR: hazard ratio; WBC: white blood cell count; HGB: hemoglobin; PLT: platelet count; ALT: alanine transaminase; AST: aspartate aminotransferase; ALP: alkaline phosphatase; CA19-9: carbohydrate antigen 19-9.
|
